Credits for processing images using Neurosetta's RosetteDetect software. One credit is for the processing of one image set; minimum order of 100 credits. Processing includes: image quality check (free), rosette detection, segmentation, and analysis, and Pax6 and DAPI cell segmentation.
The page covers Neurosetta’s latest news and events, including an Ashton lab spinoff’s work protecting the developing brain and spinal cord from toxic threats.
Neurosetta is a biotech company commercializing stem cell-derived RosetteArray technology for drug and chemical toxicity screening. It received Fast-Track STTR funding from the National Institute for Environmental Health Sciences.
Neurosetta was founded in February 2021 for commercializing RosetteArray technology, a human stem cell-derived platform for quantitative high-throughput modeling of early human brain and spinal cord development.
Neural tissue arrays enable disease modeling and quantitative high-throughput screening to identify risk factors that can perturb neurodevelopment and cause neurological disorders.
The privacy policy describes how the company collects, uses, and discloses information and explains users’ privacy rights. The company uses personal data to provide and improve the service.